CFD merupakan instrumen yang rumit dan memiliki risiko tinggi kehilangan uang secara cepat karena adanya pengaruh leverage. 84% akun investor ritel mengalami kerugian saat melakukan kegiatan perdagangan CFD dengan penyedia ini. Anda harus mempertimbangkan apakah Anda memahami cara kerja CFD dan apakah Anda mampu menerima risiko tinggi kehilangan uang.
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Perdagangan Kymera Therapeutics, Inc. - KYMR CFD

    29.62
    4.96%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.09
    Biaya inap posisi Long

    Long position overnight fee

    Margin. Your investment $1,000.00
    Biaya Overnight -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Kunjungi platform
    		-0.024874%
    Biaya inap posisi short

    Short position overnight fee

    Margin. Your investment $1,000.00
    Biaya Overnight 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Kunjungi platform
    		0.002651%
    Waktu biaya inap 21:00 (UTC)
    Kuantitas min. yang diperdagangkan 1
    Mata uang USD
    Margin 20%
    Bursa efek United States of America
    Komisi perdagangan 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 28.22
    Open* 28.57
    1-Year Change* -31.04%
    Day's Range* 28.57 - 29.62
    52 wk Range 13.15-43.67
    Average Volume (10 days) 420.76K
    Average Volume (3 months) 10.77M
    Market Cap 1.56B
    P/E Ratio -100.00K
    Shares Outstanding 55.18M
    Revenue 46.83M
    EPS -2.88
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date May 1, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Mar 31, 2023 29.62 1.38 4.89% 28.24 29.68 28.17
    Mar 30, 2023 28.22 -1.41 -4.76% 29.63 29.91 28.07
    Mar 29, 2023 29.53 1.46 5.20% 28.07 29.66 28.07
    Mar 28, 2023 28.08 -0.60 -2.09% 28.68 29.22 28.07
    Mar 27, 2023 28.73 0.00 0.00% 28.73 29.73 28.42
    Mar 24, 2023 29.30 0.88 3.10% 28.42 29.57 28.03
    Mar 23, 2023 28.81 0.33 1.16% 28.48 29.50 27.81
    Mar 22, 2023 28.05 -1.67 -5.62% 29.72 30.03 28.03
    Mar 21, 2023 30.00 -0.08 -0.27% 30.08 31.03 29.91
    Mar 20, 2023 30.71 0.74 2.47% 29.97 31.00 29.76
    Mar 17, 2023 30.98 0.89 2.96% 30.09 31.25 29.60
    Mar 16, 2023 31.01 0.35 1.14% 30.66 31.59 29.77
    Mar 15, 2023 31.10 0.26 0.84% 30.84 31.52 29.93
    Mar 14, 2023 31.57 -0.59 -1.83% 32.16 33.08 30.85
    Mar 13, 2023 31.15 2.50 8.73% 28.65 31.37 28.65
    Mar 10, 2023 29.56 -1.41 -4.55% 30.97 31.26 28.44
    Mar 9, 2023 31.66 -0.36 -1.12% 32.02 33.39 31.30
    Mar 8, 2023 33.10 1.08 3.37% 32.02 33.15 32.02
    Mar 7, 2023 32.85 0.33 1.01% 32.52 33.66 32.11
    Mar 6, 2023 32.58 0.11 0.34% 32.47 32.85 31.47

    Kymera Therapeutics, Inc. Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 46.826 72.832 34.034 2.934 0
    Revenue 46.826 72.832 34.034 2.934 0
    Total Operating Expense 208.082 173.362 80.338 45.139 21.451
    Selling/General/Admin. Expenses, Total 43.834 36.345 18.233 7.981 3.772
    Research & Development 164.248 137.017 62.105 37.158 17.679
    Operating Income -161.256 -100.53 -46.304 -42.205 -21.451
    Interest Income (Expense), Net Non-Operating 6.448 0.313 0.711 0.959 -0.016
    Net Income Before Taxes -154.808 -100.217 -45.593 -41.246 -21.467
    Net Income After Taxes -154.808 -100.217 -45.593 -41.246 -21.467
    Net Income Before Extra. Items -154.808 -100.217 -45.593 -41.246 -21.467
    Net Income -154.808 -100.217 -45.593 -41.246 -21.467
    Income Available to Common Excl. Extra. Items -154.808 -100.217 -54.643 -41.246 -21.467
    Income Available to Common Incl. Extra. Items -154.808 -100.217 -54.643 -41.246 -21.467
    Diluted Net Income -154.808 -100.217 -54.643 -41.246 -21.467
    Diluted Weighted Average Shares 53.9332 47.989 44.4822 43.1386 43.1386
    Diluted EPS Excluding Extraordinary Items -2.87036 -2.08833 -1.22842 -0.95613 -0.49763
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -2.87036 -2.08833 -1.22842 -0.95613 -0.49763
    Total Adjustments to Net Income 0 -9.05
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Total revenue 16.139 9.551 11.514 9.622 15.275
    Revenue 16.139 9.551 11.514 9.622 15.275
    Total Operating Expense 54.769 54.433 52.324 46.555 49.269
    Selling/General/Admin. Expenses, Total 11.636 10.556 11.031 10.611 11.74
    Research & Development 43.133 43.877 41.293 35.944 37.529
    Operating Income -38.63 -44.882 -40.81 -36.933 -33.994
    Interest Income (Expense), Net Non-Operating 3.765 1.88 0.553 0.249 0.094
    Net Income Before Taxes -34.865 -43.002 -40.257 -36.684 -33.9
    Net Income After Taxes -34.865 -43.002 -40.257 -36.684 -33.9
    Net Income Before Extra. Items -34.865 -43.002 -40.257 -36.684 -33.9
    Net Income -34.865 -43.002 -40.257 -36.684 -33.9
    Total Adjustments to Net Income 0
    Income Available to Common Excl. Extra. Items -34.865 -43.002 -40.257 -36.684 -33.9
    Income Available to Common Incl. Extra. Items -34.865 -43.002 -40.257 -36.684 -33.9
    Diluted Net Income -34.865 -43.002 -40.257 -36.684 -33.9
    Diluted Weighted Average Shares 57.9326 54.5355 51.7724 51.6511 51.4312
    Diluted EPS Excluding Extraordinary Items -0.60182 -0.78851 -0.77758 -0.71023 -0.65913
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -0.60182 -0.78851 -0.77758 -0.71023 -0.65913
    • Annual
    • Quarterly
    2021 2020 2019 2018
    Total Current Assets 451.273 302.339 92.845 41.79
    Cash and Short Term Investments 442.418 296.202 91.957 41.26
    Cash & Equivalents 47.976 31.004 76.015 41.26
    Short Term Investments 394.442 265.198 15.942 0
    Total Receivables, Net 0.135 1.433 0 0.148
    Prepaid Expenses 8.72 4.704 0.888 0.382
    Total Assets 605.905 487.175 116.702 44.231
    Property/Plant/Equipment, Total - Net 21.307 20.686 22.083 2.242
    Property/Plant/Equipment, Total - Gross 25.223 22.833 23.132 2.466
    Accumulated Depreciation, Total -3.916 -2.147 -1.049 -0.224
    Other Long Term Assets, Total 8.138 1.619 1.774 0.199
    Total Current Liabilities 92.542 110.617 34.57 4.687
    Accounts Payable 4.005 4.368 3.276 2.056
    Accrued Expenses 25.08 12.896 7.175 2.225
    Notes Payable/Short Term Debt 0 0 0 0
    Current Port. of LT Debt/Capital Leases 1.138 0.689 0.681 0.302
    Other Current Liabilities, Total 62.319 92.664 23.438 0.104
    Total Liabilities 146.267 203.287 82.028 5.238
    Total Long Term Debt 1.14 0.604 1.165 0.393
    Capital Lease Obligations 1.14 0.604 1.165 0.393
    Other Liabilities, Total 52.585 92.066 46.293 0.158
    Total Equity 459.638 283.888 34.674 38.993
    Redeemable Preferred Stock 109.08 73.429
    Common Stock 0.005 0.004 0 0
    Additional Paid-In Capital 689.275 412.777 2.044 0.774
    Retained Earnings (Accumulated Deficit) -228.982 -128.765 -76.456 -35.21
    Other Equity, Total -0.66 -0.128 0.006 0
    Total Liabilities & Shareholders’ Equity 605.905 487.175 116.702 44.231
    Total Common Shares Outstanding 51.5362 44.4822 43.1386 43.1386
    Accounts Receivable - Trade, Net 0.135 0.856
    Long Term Investments 125.187 162.531
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 431.382 451.273 543.731 364.806 340.791
    Cash and Short Term Investments 420.812 442.418 536.386 359.107 333.537
    Cash & Equivalents 33.733 47.976 156.819 84.903 53.098
    Short Term Investments 387.079 394.442 379.567 274.204 280.439
    Total Receivables, Net 1.263 0.135 1.573 0.904 1.734
    Accounts Receivable - Trade, Net 1.263 0.135 1.573 0.904 0.878
    Prepaid Expenses 9.307 8.72 5.772 4.795 5.52
    Total Assets 563.06 605.905 642.453 434.386 464.552
    Property/Plant/Equipment, Total - Net 21.066 21.307 21.724 21.766 20.502
    Property/Plant/Equipment, Total - Gross 25.668 25.223 24.951 24.942 23.127
    Accumulated Depreciation, Total -4.602 -3.916 -3.227 -3.176 -2.625
    Long Term Investments 102.478 125.187 74.692 45.305 101.639
    Other Long Term Assets, Total 8.134 8.138 2.306 2.509 1.62
    Total Current Liabilities 88.339 92.542 94.493 108.685 110.137
    Accounts Payable 2.567 4.005 5.033 8.177 8.348
    Accrued Expenses 22.913 25.08 21.105 16.838 12.962
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 1.087 1.138 1.189 1.038 0.64
    Other Current Liabilities, Total 61.772 62.319 67.166 82.632 88.187
    Total Liabilities 134.34 146.267 159.318 176.282 189.305
    Total Long Term Debt 0.927 1.14 1.347 1.145 0.498
    Capital Lease Obligations 0.927 1.14 1.347 1.145 0.498
    Other Liabilities, Total 45.074 52.585 63.478 66.452 78.67
    Total Equity 428.72 459.638 483.135 258.104 275.247
    Common Stock 0.005 0.005 0.005 0.005 0.004
    Additional Paid-In Capital 697.597 689.275 678.358 424.599 417.096
    Retained Earnings (Accumulated Deficit) -265.666 -228.982 -195.082 -166.5 -141.84
    Other Equity, Total -3.216 -0.66 -0.146 0 -0.013
    Total Liabilities & Shareholders’ Equity 563.06 605.905 642.453 434.386 464.552
    Total Common Shares Outstanding 51.6927 51.5362 51.2565 45.3277 44.8794
    • Annual
    • Quarterly
    2021 2020 2019 2018
    Net income/Starting Line -100.217 -45.593 -41.246 -21.467
    Cash From Operating Activities -128.946 88.13 17.905 -17.863
    Cash From Operating Activities 2.397 1.763 0.825 0.205
    Non-Cash Items 30.797 7.093 1.639 1.091
    Cash Interest Paid 0.158 0.115 0.046 0.015
    Changes in Working Capital -61.923 124.867 56.687 2.308
    Cash From Investing Activities -99.835 -422.588 -16.486 -1.356
    Capital Expenditures -1.597 -9.096 -0.532 -1.356
    Other Investing Cash Flow Items, Total -98.238 -413.492 -15.954 0
    Cash From Financing Activities 250.28 289.262 34.911 52.932
    Issuance (Retirement) of Stock, Net 249.18 276.289 35.282 53.227
    Issuance (Retirement) of Debt, Net -0.849 -0.554 -0.371 -0.295
    Net Change in Cash 21.499 -45.196 36.33 33.713
    Financing Cash Flow Items 1.949 13.527
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -36.684 -100.217 -66.317 -37.735 -13.075
    Cash From Operating Activities -40.295 -128.946 -90.594 -53.334 -22.823
    Cash From Operating Activities 0.687 2.397 1.708 1.037 0.485
    Non-Cash Items 9.048 30.797 20.483 11.409 4.451
    Cash Interest Paid 0.046 0.158 0.106 0.054 0.024
    Changes in Working Capital -13.346 -61.923 -46.468 -28.045 -14.684
    Cash From Investing Activities 25.863 -99.835 -31.816 105.046 44.323
    Capital Expenditures -0.482 -1.597 -1.096 -0.79 -0.164
    Other Investing Cash Flow Items, Total 26.345 -98.238 -30.72 105.836 44.487
    Cash From Financing Activities 0.185 250.28 248.226 2.187 0.595
    Financing Cash Flow Items 0 1.949 1.95 -0.397 -0.397
    Issuance (Retirement) of Stock, Net 0.449 249.18 246.969 2.925 1.147
    Issuance (Retirement) of Debt, Net -0.264 -0.849 -0.693 -0.341 -0.155
    Net Change in Cash -14.247 21.499 125.816 53.899 22.095
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Atlas Venture Venture Capital 10.6159 5858262 -126474 2023-01-12 LOW
    BVF Partners L.P. Hedge Fund 8.5779 4733611 41007 2023-01-12 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 8.3197 4591089 1180703 2022-12-31 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 7.8899 4353945 277562 2022-12-31 LOW
    Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 6.9767 3850000 1680770 2022-12-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.619 3652608 797130 2022-12-31 LOW
    Vertex Pharmaceuticals Inc Corporation 5.8007 3201049 49928 2022-03-31
    Baker Bros. Advisors LP Hedge Fund 5.2186 2879825 0 2022-12-31 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.1577 2846221 160817 2022-12-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.1454 2839421 172415 2022-12-31 LOW
    Redmile Group, LLC Investment Advisor/Hedge Fund 4.8453 2673837 -202800 2022-12-31 LOW
    Invus Public Equities Advisors, LLC Investment Advisor 3.6243 2000000 500000 2022-12-31 LOW
    T. Rowe Price Investment Management, Inc. Investment Advisor 3.5445 1955977 -40552 2022-12-31 MED
    Rock Springs Capital Management LP Hedge Fund 2.2249 1227779 181036 2022-12-31 LOW
    Fidelity Management & Research Company LLC Investment Advisor 1.5331 846046 520360 2022-12-31 LOW
    Wasatch Global Investors Inc Investment Advisor/Hedge Fund 1.5081 832221 -228340 2022-12-31 LOW
    EcoR1 Capital, LLC Hedge Fund 1.4426 796093 0 2022-12-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3538 747071 45849 2022-12-31 LOW
    Mellon Investments Corporation Investment Advisor/Hedge Fund 1.2316 679621 -41254 2022-12-31 LOW
    Aquilo Capital Management, LLC Investment Advisor/Hedge Fund 1.1406 629411 299165 2022-12-31 LOW

    Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.

    Capital.com Group

    500K+

    Trader

    92K+

    Klien aktif per bulan

    $53M+

    Volume investasi per bulan

    $30M+

    Penarikan tiap bulan

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Laba/Loss
    Industry: Biotechnology & Medical Research (NEC)

    200 Arsenal Yards Blvd., Suite 230
    2Nd Floor
    WATERTOWN
    MASSACHUSETTS 02472
    US

    Income Statement

    • Annual
    • Quarterly

    People also watch

    Natural Gas

    2.20 Price
    +3.540% 1D Chg, %
    Biaya inap posisi Long -0.4092%
    Biaya inap posisi short 0.3873%
    Waktu biaya inap 21:00 (UTC)
    Spread 0.005

    Oil - Crude

    75.76 Price
    +1.830% 1D Chg, %
    Biaya inap posisi Long -0.0156%
    Biaya inap posisi short -0.0063%
    Waktu biaya inap 21:00 (UTC)
    Spread 0.03

    US100

    13,186.80 Price
    +1.680% 1D Chg, %
    Biaya inap posisi Long -0.0249%
    Biaya inap posisi short 0.0027%
    Waktu biaya inap 21:00 (UTC)
    Spread 3.0

    Gold

    1,969.66 Price
    -0.550% 1D Chg, %
    Biaya inap posisi Long -0.0185%
    Biaya inap posisi short 0.0102%
    Waktu biaya inap 21:00 (UTC)
    Spread 0.30

    Masih mencari broker yang bisa Anda percayai?

    Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com

    1. Buat & verifikasi akun Anda 2. Lakukan deposit 3. Temukan trading Anda